Session Abstract – PMWC 2018 Silicon Valley
Session Synopsis: AACR Project GENIE is an international cancer registry of real-world data assembled through data sharing between eight of the world’s leading cancer centers. The consortium is committed to open science, and makes all data publicly available. This session will focus on answering various questions in precision medicine using the registry.
Session Chair Profile
M.D., Ph.D., Assistant Professor of Pathology, Urology and Oncology, Johns Hopkins University School of Medicine
Alexander Baras, M.D., Ph.D., is a pathologist and informatics/bioinformatics expert who leads the precision medicine efforts within the Sidney-Kimmel Comprehensive Cancer Center at Johns Hopkins. He serves as the Associate Director of Informatics for the Department of Pathology at Johns Hopkins. He also directs the Digital Pathology Research Core facility along with the Digital Pathology Clinical Service at Johns Hopkins. Dr. Baras completed his MD/PhD at the University of Virginia and his residency and fellowship training in Anatomic Pathology at Johns Hopkins University Medical School.
The implementation of high-throughput, analytic methodologies for various biomolecules is ushering in a new era of discovery in disease pathogenesis. Leveraging these technologies in the development of novel diagnostics and therapeutic approaches is the crux of “precision medicine”. We are now more than ever uniquely poised to detect previously unidentified features of disease that can better guide patient management, whether their modality be based on tissue morphology, protein expression, RNA analysis, genomic analysis, and the interaction of evolving malignancies with the host immune system.
Ph.D., Executive Director, Khalifa Institute for Personalized Cancer Therapy, MD Anderson
Dr. Shaw is executive director of the Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy (Khalifa Institute). She joined The University of Texas MD Anderson Cancer Center in 2013, bringing an extensive background in science leadership and education. Prior to joining MD Anderson, Dr. Shaw spent four years with The Cancer Genome Atlas (TCGA), a flagship project of the National Cancer Institute focused on accelerating understanding of the molecular basis of cancer. Dr. Shaw earned undergraduate degrees in Spanish and Biology at the College of William and Mary, and completed her doctoral degree in cell and developmental biology at Harvard University.
Ph.D., FACMG, Scientist, Princess Margaret Cancer Centre / Assistant Professor, University of Toronto
Dr. Pugh is a cancer genomics researcher and board-certified molecular geneticist, with a research program encompassing discovery-oriented cancer genome characterization, development and application of genomic methods, and a supporting role in the clinical practice of genomic medicine including data sharing. He a Scientist at the Princess Margaret Cancer Centre and Assistant Professor in the University of Toronto Department of Medical Biophysics. He is also Scientific Director of the Princess Margaret Genomics Centre and Co-Director of the Translational Genomics Laboratory, a joint initiative with the Ontario Institute for Cancer Research to enable clinically-oriented genomics projects. Dr. Pugh serves on advisory committees for Cancer Care Ontario, Canadian Clinical Trials Group, HPC4Health, and the BC Cancer Agency Personalized OncoGenomics Program. He has participated in multiple large-scale genomics and data-sharing programs including AACR GENIE, TCGA, and NCI TARGET. In 2017, he received a Terry Fox New Investigator Award.